ATXI IPOs 6.33M* shares @$6:00: https://finance.yahoo.com/news/avenue-therapeutics-prices-initial-public-233000323.html Avenue [Therapeutics] is a New York-based, specialty pharmaceutical company focused on the development and commercialization of an intravenous formulation of tramadol HCl…for the management of moderate to moderately severe postoperative pain. Avenue Therapeutics completed pharmacokinetics and End-of-Phase 2 studies for IV Tramadol in 2016, and plan to initiate a Phase 3 development program of IV Tramadol this year.*Assuming exercise of underwriter's option.